Xpress Biologics now part of Sartorius

Xpress Biologics, Polyplus compagny and now part of Sartorius, is a biotech company proposing contract services for the production of recombinant proteins, antibody fragments and plasmid DNA for preclinical applications (therapeutic and diagnostic markets). The production scale goes from 100 mg up to 10 g with, depending of the use of the biologics, “R&D” and “GLP” qualities. The production processes proposed by Xpress Biologics are all developed in microbial expression system, E. coli (soluble cytoplasmic, inclusion bodies and periplasmic productions) and P. pastoris (secreted protein) mainly. These processes are IP free and take into account the regulatory and industrial (scale-up) requirements which facilitate the transfer of the project to CMOs (Contract Manufacturing Organizations) for the production of “GMP” grade material if necessary. Xpress Biologics acts as One-Stop-Shop and can, through project management with defined subcontractors, take in charge additional services as the screening and development of antibodies against specific targets, the production of “GMP” grade material, the organization of pre-clinical and clinical studies.

Website

http://www.xpress-biologics.com

External link for Xpress Biologics now part of Sartorius

Industry

Biotechnology Research

Company size

11-50 employees

Headquarters

Milmort, Province de Liège

Type

Privately Held

Founded

2014

Specialties

Protein production, Antibody fragment production, Plasmid DNA production, Contract Service, Microbial fermentation, GLP manufacturing, Diagnostic, Pre-clinical applications, and GMP